Monopar Therapeutics

29 articles with Monopar Therapeutics

• Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

  3/30/2021

  Monopar Therapeutics Inc. announced the publication of a peer-reviewed study titled “Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.” Urokinase plasminogen activator is an established biomarker in current breast cancer clinical practice guidelines and its presence is used to select appropriate drug treatment.

• Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates

  3/25/2021

  Validive ® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer

• Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery- Initial focus on use in bladder cancer surgery

  3/2/2021

  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has entered into an agreement with serial medtech entrepreneur, Andrew Cittadine, to explore over the next few months strategic and developmental options for MNPR-101 as an intraoperative imaging agent in bladder cancer

• Monopar Therapeutics to Present at Upcoming Investor Conferences

  2/24/2021

  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March: H.C. Wainwright Global Life Sciences Conference

• Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical OperationsLaura Kelly’s Extensive Experience to Benefit Monopar’s Phase 2b/3 VOICE Trial

  2/18/2021

  Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, announced the appointment of Laura Kelly as Director of Clinical Operations.

• Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

  2/16/2021

  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has dosed the first patient in its Phase 2b/3 VOICE trial of Validive ® for the prevention of chemoradiotherapy-induced severe oral mucositis in pat ents with oropharyngeal cancer (VOICE).

• Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

  2/11/2021

  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study in the European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer.

• Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

  2/9/2021

  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life and improve the quality of life for cancer patients, today announced the issuance of a patent covering composition of matter for MNPR-101 in Canada, adding to its existing protection in key markets around the world including the US, Europe and Japan.

• Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

  12/22/2020

  Monopar Therapeutics today announced the issuance of a U.S. patent (US 10,450,340) covering compositions of matter for a novel family of camsirubicin analogs.

• Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)

  12/8/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that its Phase 2b/3 clinical trial of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer (VOICE) is active and recruiting patients.

• Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

  11/12/2020

  Validive ® Phase 2b/3 Clinical Trial on Track to Start Before Year-end Issuance of New Patents For Validive Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021 WILMETTE, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today annou

• Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®Strengthens Monopar’s Validive IP Portfolio To 2035

  11/9/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced a series of recently issued patents for its Phase 2b/3 clinical-stage lead product candidate, Validive (clonidine HCl mucobuccal tablet). These patents, including U.S. Patent No. 10,675,271, provide claims covering

• Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020

  9/14/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 22 nd Annual Global Investment Conference, Healthcare & Biotech Track. The conference will be held virtually. Presentation Details: Date: Wednesday, September 16, 2020 Time: 1:30 PM EDT Location: Virtual https://hcwevents.com/ For more information, please

• Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19

  9/9/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a collaboration with The University of Texas Health Science Center at Tyler (UTHSCT) and its Texas Lung Injury Institute (TLII)

• Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19

  8/19/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of u rokinase p lasminogen activator receptor targeted r adio- i mmuno- t herapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a partnership with Aragen Bioscience, Inc. (Morgan Hill, CA),  a leading contra

• Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented TechnologyPotential Companion Diagnostic to Monopar’s uPRIT Program

  8/12/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus unlikely to progress to severe respiratory failure.

• Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19

  8/10/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to treat patients with severe COVID-19, today announced a partnership with IsoTherapeutics Group, LLC (Angleton, TX), to develop and manufacture a RIT for the potential treatment of severe COVID-19. IsoTherapeutics will m

• Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business UpdatesCollaboration Formed to Develop COVID-19 Therapeutic with Monopar’s Proprietary MNPR-101 Technology

  8/6/2020

  Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, announced second quarter 2020 financial results and business updates.

• Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR

  6/30/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a provisional patent application entitled “Precision Radioimmunotherapeutic Targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for Treatment of Severe COVID-19 Disease” has been filed with the U.S. Patent and Trademark Office (USPTO). This application covers novel compositions and uses of cy

• Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19

  6/16/2020

  Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection). Monopar is a clinical-stage biopharmaceutical company and NorthStar is a commercial producer and supplier of medical radioisotopes. This collaboration combines NorthStar’s ex